C4 THERAPEUTICS, INC.
WATERTOWN -
Details of the posters are as follows
Title: CFT1946, a potent, selective BRAF V600X mutant-specific degrader demonstrates superior activity as a single agent to clinically approved BRAF inhibitors and standard of care combinations in preclinical models of BRAF V600X melanoma, CRC, NSCLC, and brain metastasis
Abstract Number: 1658
Session Date and Time:
Location: Poster Section 14
Session Title: Cell Signaling Components as Therapeutic Targets
Presenter:
Title: CFT8634, a BRD9 BiDAC degrader, is active in a subset of multiple myeloma cell line models and synergistic when combined with pomalidomide or dexamethasone
Abstract Number: 6064
Session Date and Time:
Location: Poster Section 30
Session Title: Targeted Protein Degraders
Presenter:
In
About
About CFT1946
CFT1946 is an orally bioavailable BiDAC degrader designed to be potent and selective against BRAF V600X mutant targets. In preclinical studies, CFT1946 is active in vivo and in vitro in models with BRAF V600E-driven disease and in models resistant to BRAF inhibitors. CFT1946 is currently in a Phase 1 dose escalation study in BRAF V600 mutant solid tumors including non-small cell lung cancer, colorectal cancer and melanoma.
Contact:
Email: CSolberg@c4therapeutics.com
Email: LSpreen@c4therapeutics.com
(C) 2024 Electronic News Publishing, source
